28
Oct
2025

Zentiva Group, a.s.

Exhibitor at CPHI Frankfurt 2025 stand 3.0G20, Finished Dosage Formulations
About Us

Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,500 people and a network of production sites - including flagship sites in Prague, Bucharest and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people’s daily healthcare needs. At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high quality affordable medicines and healthcare. We work in partnership with physicians,...

  • CZ
  • 2019
    On CPHI since
Contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 3.0G20, Finished Dosage Formulations

Products Featured at CPHI Frankfurt 2025

  • Zent2U - Zentiva B2B Platform

    Product Zent2U - Zentiva B2B Platform

    Zent2U (www.zent2u.com) is a B2B platform of Zentiva established in 2019 to collaborate with customers on:

    - Licensing-out dossiers developed by Zentiva

    - Co-development opportunities by co-financing Zentiva's products in development

    - CMO services by Zentiva in production ...
  • Value Added Dasatinib

    Product Value Added Dasatinib

    Value added Dasatinib (Teaser attached)  •  Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)  •  Current available products on the market are not completely absorbed by those patients ...
  • Value Added Abiraterone

    Product Value Added Abiraterone

    Value added Abiraterone  •  Abiraterone is a medication used to treat prostate cancer  •  The recommended dose is 1,000 mg as a single daily dose that must not be taken with food.  •  Administering  with food results up to a 10-fold (AUC) and up to a 17-fo...
  • Innovative combination Finasteride + Tadalafil

    Product Innovative combination Finasteride + Tadalafil

    Innovative combination Finasteride + Tadalafil   • Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe.  • The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of the...
  • CDMO

    Product CDMO

    Services.